… rivaroxaban in Asian patients. In summary, our meta-analysis showed that Asian patients with
non-valvular AF on rivaroxaban … stroke and bleeding rates compared to those on warfarin. …

… among Asian patients with NVAF, we found that edoxaban, apixaban, and rivaroxaban were
… lower risk of ICH and major bleeding than warfarin. There was consistency even among high…

… Dabigatran and Rivaroxaban among Asian patients with AF in terms of e cacy and safety is
… clinical e cacy and safety of Dabigatran versus Rivaroxaban in Asian patients with AF by a …

… The purpose of this study was to investigate the effectiveness and safety of NOACs in Asian
… and warfarin users as well as the effectiveness and safety of individual NOACs to warfarin. …

… exists on the effectiveness and safety of warfarin and all 4 … Asian population with nonvalvular
atrial fibrillation. We aimed to evaluate the comparative effectiveness and safety of warfarin …

… that compared four DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) with warfarin
in Asian patients with regard to both effectiveness and safety outcomes. Overall, DOACs …

… NMA for Asians with NVAF suggested apixaban, dabigatran, and rivaroxaban were more
effective than warfarin on reducing the risks of stroke and haemorrhage; apixaban appeared to …

… , limited evidence exists on the effectiveness and safety of warfarin and all 4 available … the
Asian population. We aimed to evaluate comparative effectiveness and safety of warfarin and …

… , was an international registry that included patients from Asia, Europe, North America, and
Latin … at least three NOACs (apixaban, dabigatran, and rivaroxaban) with warfarin. Data were …

… To assess the efficacy and safety of NOACs versus warfarin in Asian patients with AF, we
included the following clinical outcomes: (1) thromboembolic events, including stroke or …